Colony Group’s Fate Therapeutics FATE Stock Holding History

Colony Group’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,906	Closed	-$114K	–	765
2023 Q2	$114K	Hold	23,906	–	–	﹤0.01%	747
2023 Q1	$136K	Buy	+23,906	New	+$144K	﹤0.01%	760

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Colony Group's FATE Position: Q3 2023 in Review

Colony Group sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 23,906 shares — an estimated $114K sold.

Colony Group first reported a position in FATE in Q1 2023 and held it in 2 quarters. The position peaked at $136K in Q1 2023. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

Colony Group reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
Colony Group sold 23,906 Fate Therapeutics shares in Q3 2023, an estimated $114K.
Colony Group first reported a position in Fate Therapeutics in Q1 2023 and held it in 2 quarters.
Colony Group's Fate Therapeutics position peaked at $136K in Q1 2023.
170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.